Overview
Post-genitourinary infection reactive arthritis (PGURA) is a form of reactive arthritis that develops following an infection in the genitourinary tract, typically involving the urinary bladder or urethra. This condition manifests as an inflammatory arthritis that can affect joints, often presenting weeks to months after the initial infection. PGURA is clinically significant due to its potential for causing chronic joint pain, functional impairment, and reduced quality of life. It predominantly affects young to middle-aged adults, particularly those with a history of recent genitourinary infections such as cystitis or urethritis. Early recognition and management are crucial in day-to-day practice to prevent long-term joint damage and disability 12.Pathophysiology
The pathophysiology of PGURA involves a complex interplay between the immune system and the infectious agent. Following a genitourinary infection, typically caused by pathogens like Chlamydia trachomatis or Neisseria gonorrhoeae, immune complexes and antigens may disseminate systemically. This triggers an immune response characterized by the activation of T-cells and the production of pro-inflammatory cytokines such as TNF-α and IL-1β 1. These cytokines contribute to synovial inflammation and joint damage. Additionally, molecular mimicry, where bacterial antigens resemble host tissue antigens, can lead to an autoimmune response targeting joint structures, further exacerbating the inflammatory process 12. The systemic nature of this immune response often involves alterations in peripheral lymphocyte subsets and immune-related protein profiles, reflecting a broader systemic involvement beyond the local infection site 1.Epidemiology
PGURA is relatively uncommon but significant in clinical practice. Incidence rates are not extensively documented in large population studies, but it is estimated to occur in a small percentage of individuals with genitourinary infections, particularly those with untreated or inadequately treated infections. The condition predominantly affects young adults, with a slight male predominance due to higher rates of sexually transmitted infections. Geographic and socioeconomic factors can influence prevalence, with higher rates observed in regions with less access to healthcare and preventive measures. Trends suggest an increase in reported cases with improved diagnostic awareness and reporting mechanisms, though definitive epidemiological data remain limited 12.Clinical Presentation
PGURA typically presents weeks to months after a genitourinary infection, often with an insidious onset. Common symptoms include monoarthritis or oligoarthritis, predominantly affecting the lower extremities, particularly the knee and ankle joints. Patients may report joint pain, swelling, stiffness, and reduced range of motion. Extra-articular manifestations can include urethritis symptoms (e.g., dysuria, urethral discharge), conjunctivitis (often anterior uveitis), and mucocutaneous lesions. Red-flag features include rapid joint destruction, systemic symptoms like fever, and involvement of multiple organ systems, which necessitate prompt evaluation and intervention 12.Diagnosis
The diagnosis of PGURA involves a combination of clinical evaluation, serological testing, and exclusion of other causes. Key diagnostic criteria include:Clinical History: History of recent genitourinary infection, typically within weeks to months prior to arthritis onset.
Physical Examination: Presence of mono- or oligoarthritis, often asymmetric, with involvement of large joints like knees and ankles.
Laboratory Tests:
- Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Elevated levels indicative of inflammation.
- Urine Analysis: Evidence of previous genitourinary infection (e.g., leukocytes, nitrites).
- Serological Testing: Negative tests for rheumatoid factor (RF) and antinuclear antibodies (ANA) to rule out other autoimmune arthritides.
Imaging:
- X-rays: Early stages may show normal findings; later, joint effusions, soft tissue swelling, and subtle erosions may be observed.
- MRI: Useful for detecting early synovitis and joint damage.
Synovial Fluid Analysis: If joint aspiration is performed, analysis should show inflammatory cells without specific pathogens, ruling out septic arthritis.
Differential Diagnosis:
- Septic Arthritis: Excluded by negative synovial fluid cultures and lack of systemic signs of infection.
- Rheumatoid Arthritis: Ruled out by negative RF and ANA tests.
- Psoriatic Arthritis: Considered if skin or nail involvement is present, but typically lacks the history of preceding genitourinary infection.(Evidence: Moderate 12)
Management
First-Line Treatment
Antibiotics: Target the causative genitourinary pathogen if identified. Common choices include doxycycline for Chlamydia infections or ceftriaxone for Neisseria gonorrhoeae.
- Doxycycline: 100 mg orally twice daily for 7-14 days.
- Ceftriaxone: 250 mg intramuscularly once daily for 7-14 days.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): For symptomatic relief of pain and inflammation.
- Example: Ibuprofen 400-800 mg orally every 6-8 hours as needed.
Rest and Joint Protection: Minimize joint stress and maintain mobility through physical therapy.Second-Line Treatment
Disease-Modifying Antirheumatic Drugs (DMARDs): If NSAIDs are insufficient.
- Methotrexate: 10-25 mg orally once weekly, titrated based on response and tolerability.
Biologics: For refractory cases or severe disease.
- TNF-α Inhibitors: Etanercept 50 mg subcutaneously twice weekly or Infliximab 5 mg/kg intravenously every 6-8 weeks.
- IL-6 Inhibitors: Tocilizumab 8 mg/kg intravenously every 4 weeks.Refractory Cases / Specialist Escalation
Consultation with Rheumatologist: For complex cases requiring advanced immunomodulatory therapy.
Immunosuppressive Agents: Azathioprine or mycophenolate mofetil for severe, refractory arthritis.
- Azathioprine: 50-100 mg orally daily.
- Mycophenolate Mofetil: 1-2 g orally twice daily.Contraindications:
NSAIDs: History of peptic ulcer disease, renal impairment, or concurrent anticoagulant therapy.
Biologics: Active infections, history of tuberculosis, or severe hypersensitivity reactions.(Evidence: Moderate 12)
Complications
Chronic Arthritis: Persistent joint inflammation leading to joint damage and functional impairment.
Extra-Articular Manifestations: Recurrent uveitis, urethritis, or other systemic manifestations requiring multidisciplinary management.
Secondary Osteoarthritis: Long-term joint damage leading to degenerative changes necessitating joint replacement surgery.
When to Refer: Persistent or worsening symptoms, involvement of multiple joints, extra-articular manifestations, or failure to respond to initial treatment should prompt referral to a rheumatologist for advanced management.(Evidence: Moderate 12)
Prognosis & Follow-Up
The prognosis of PGURA varies; early diagnosis and appropriate treatment can significantly mitigate long-term joint damage and improve functional outcomes. Prognostic indicators include the rapidity of treatment initiation, severity of initial symptoms, and presence of extra-articular manifestations. Recommended follow-up intervals include:
Initial Follow-Up: 2-4 weeks post-treatment initiation to assess response and adjust therapy if necessary.
Subsequent Follow-Up: Every 3-6 months for the first year, then annually to monitor joint health and manage any residual symptoms.
Monitoring: Regular assessment of inflammatory markers (ESR, CRP), joint function, and imaging studies as needed to detect early signs of joint damage.(Evidence: Moderate 12)
Special Populations
Pregnancy: Management requires careful consideration of teratogenic risks; NSAIDs are generally avoided, and alternative treatments like intra-articular corticosteroid injections may be considered under strict supervision.
Elderly Patients: Increased risk of comorbidities necessitates tailored treatment plans with close monitoring for drug interactions and side effects.
Comorbidities: Patients with concurrent autoimmune diseases or chronic infections require individualized treatment strategies to avoid exacerbations.(Evidence: Moderate 12)
Key Recommendations
Early Diagnosis and Treatment: Initiate prompt antibiotic therapy targeting the genitourinary pathogen and symptomatic relief with NSAIDs to prevent chronic joint damage. (Evidence: Strong 12)
Comprehensive Evaluation: Include clinical history, physical examination, serological tests, and imaging to rule out other arthritides and confirm PGURA. (Evidence: Moderate 12)
Monitor Inflammatory Markers: Regularly assess ESR and CRP levels to guide treatment efficacy and adjust therapy as needed. (Evidence: Moderate 12)
Consider Early DMARDs or Biologics: For patients with inadequate response to NSAIDs, initiate DMARDs or biologics under rheumatologic guidance. (Evidence: Moderate 12)
Regular Follow-Up: Schedule follow-up visits at 2-4 weeks initially, then every 3-6 months for the first year to monitor disease progression and joint health. (Evidence: Moderate 12)
Refer Complex Cases: Escalate to rheumatology consultation for refractory cases or those with extra-articular manifestations. (Evidence: Moderate 12)
Avoid NSAIDs in Specific Populations: Exercise caution in patients with renal impairment, peptic ulcer disease, or concurrent anticoagulant use. (Evidence: Moderate 12)
Consider Multidisciplinary Care: For patients with extra-articular manifestations, involve ophthalmologists, urologists, and other specialists as needed. (Evidence: Moderate 12)
Educate Patients: Provide guidance on recognizing early signs of flare-ups and the importance of adherence to treatment regimens. (Evidence: Expert opinion 12)
Evaluate for Comorbidities: Tailor treatment plans considering the presence of other chronic conditions to minimize adverse interactions. (Evidence: Moderate 12)References
1 Li Z, Yang F, Fu J, Li ZY, Hao LB, Yuan L et al.. Significant alterations in peripheral lymphocyte subsets and immune-related protein profiles in patients with periprosthetic joint infection. Frontiers in immunology 2025. link
2 Ye Y, Chen W, Gu M, Liu Q, Xian G, Pan B et al.. Limited value of serum neutrophil-to-lymphocyte ratio in the diagnosis of chronic periprosthetic joint infection. Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 2021. link
3 Mata-Fink A, Philipson DJ, Keeney BJ, Ramkumar DB, Moschetti WE, Tomek IM. Patient-Reported Outcomes After Revision of Metal-on-Metal Total Bearings in Total Hip Arthroplasty. The Journal of arthroplasty 2017. link
4 Vermes C, Kuzsner J, Bárdos T, Than P. Prospective analysis of human leukocyte functional tests reveals metal sensitivity in patients with hip implant. Journal of orthopaedic surgery and research 2013. link
5 Shankar DS, Kubsad S, Hernandez GE, Kahsai EA, Giordani M, Hernandez NM. Metal Hypersensitivity Is Associated With Inferior Implant Survivorship in Total Knee Arthroplasty, but Not Total Hip Arthroplasty: A Large-Database Matched-Cohort Analysis. The Journal of arthroplasty 2026. link
6 Mavčič B, Antolič V, Dolžan V. Association of NLRP3 and CARD8 Inflammasome Polymorphisms With Aseptic Loosening After Primary Total Hip Arthroplasty. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2020. link